Abstract 66P
Background
Treatment options are limited for patients with advanced or metastatic solid tumors after failure of standard therapies. Utidelone, a genetically engineered epothilone analogue, has demonstrated high activity in clinical studies against a broad range of tumors using regimen of 30mg/m2, iv, d1-5 every 21 day. This study aimed to evaluate the efficacy and safety for solid tumors using 120h continuous intravenous infusion of utidelone.
Methods
This is a prospective, multicenter, single-arm trial. We included patients aged 18 years or older with metastatic solid tumor after failure of standard therapies. Utidelone was administrated at 150 mg/m2 via 120h continuous intravenous infusion, alone or in combination with other anticancer agents every 21 days until disease progression or intolerable toxicity. The primary endpoints were ORR and safety. Secondary endpoints included mPFS, DCR and QoL.
Results
As data cut-off on June 30, 2023, a total of 50 patients were enrolled and analyzed. There were 20 patients with breast cancers,11 with gynecological cancers, 8 with gastrointestinal cancers, 6 with lung cancer and 5 with other solid tumors. The median number of previous systemic therapies was three. 38 (76%) patients had taxane-refractory diseases. The overall ORR and DCR was 20% and 66%, respectively, the mPFS was 4 months. For breast cancer patients, the ORR and DCR was 40% and 75%, respectively, and the mPFS was 6 months. For gynecological cancers, the ORR and DCR was 9% and 64%, respectively. Most of the AEs were grade 1 or 2 and were manageable and reversible. The rate of grade ≥3 AEs including peripheral neuropathy was 4% (2/50). No treatment-related discontinuation or deaths occurred.
Conclusions
This study demonstrated a promising anti-tumor activity of utidelone in patients with metastatic solid tumors after failure of the standard therapies, especially in patients with breast cand gynecological cancers. Moreover, 120h continuous intravenous infusion is a more tolerable administration method than 5 days intermittent infusion, worthy further study.
Clinical trial identification
ChiCTR2300074299.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract